Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOrnjira Arusksakunwongen_US
dc.contributor.authorSiriporn Promsrien_US
dc.contributor.authorKitiyaporn Wittayanarakulen_US
dc.contributor.authorPiyarat Nimmanpipugen_US
dc.contributor.authorVannajan S. Leeen_US
dc.contributor.authorAtchara Wijitkosoomen_US
dc.contributor.authorPornthep Sompornpisuten_US
dc.contributor.authorSupot Hannongbuaen_US
dc.description.abstractAlthough a number of potent and selective inhibitors have been developed and approved as drugs for the treatment of HIV infection, efforts still needed in order to develop new inhibitors that are more potent, have unique resistance patterns, and minimal side effects. This review focuses to the HIV-1 protease (HIV-1 PR), the enzyme belongs to the family of aspartic acid based on the identification of the Asp-Thr-Gly catalytic triad. In the fast part, general features of the HIV-1 PR as well as its structure and functions were given. Afterwards, the review was targeted to discovery, characteristic, activity and emergence of drug resistant of the nine FDA (Food and Drug Administration) approval inhibitors, indinavir, saquinavir, nelfinavir, ritonavir, lopinavir, amprenavir, tipranavir, atazanavir and fosamprenavir. In addition, the two promising inhibitors (brecanavir, darunavir), which are currently under development, as well as a competitive non-peptide based inhibitors (water soluble C60 derivatives) were also introduced. © 2007 Bentham Science Publishers Ltd.en_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleCurrent development on HIV-1 protease inhibitorsen_US
article.title.sourcetitleCurrent Computer-Aided Drug Designen_US
article.volume3en_US Universityen_US Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.